Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 8;33(4):222–227. doi: 10.1002/clc.20724

Comparison of Effects of Simvastatin Versus Atorvastatin on Oxidative Stress in Patients With Coronary Heart Disease

Jia Li 1, Yan‐Ming Sun 1, Lan‐Feng Wang 1,✉, Zhu‐Qin Li 1, Wei Pan 1, Hong‐Yan Cao 2
PMCID: PMC6653572  PMID: 20394043

Abstract

Background

HMG‐CoA reductase inhibitors (statins) have antiatherogenic effects beyond their cholesterol‐lowing effect. Whether atorvastatin has a stronger antioxidant effect than other statins is uncertain.

Hypothesis

To determine the effects of simvastatin and atorvastatin on markers of oxidative stress in patients with coronary heart disease (CHD).

Methods

This study was comprised of 164 patients with CHD and a control population of 122 healthy subjects. The patients with CHD were divided into 2 groups and treated with either simvastatin 20 mg/day or atorvastatin 10 mg/day. The markers of oxidative stress were measured before and after 12 weeks of treatment.

Results

The effects of atorvastatin on reducing oxidative stress were significantly greater compared with those of simvastatin (P < 0.05). The changes in the markers of oxidative stress did not correlate with the changes in the plasma lipid profile (P > 0.05).

Conclusions

This study suggests that atorvastatin reduces oxidative stress more effectively than simvastatin. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (166.3 KB).

References

  • 1. Wenger NK, Shaw LJ, Vaccarino V. Coronary heart disease in women: update 2008. Clin Pharmacol Ther 2008; 83: 37–51. [DOI] [PubMed] [Google Scholar]
  • 2. Ishibashi Y, Takahashi N, Tokumaru A, et al. Effects of long‐term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease. J Cardiovasc Pharmacol 2008; 51: 311–316. [DOI] [PubMed] [Google Scholar]
  • 3. Buijsse B, Feskens EJ, Moschandreas J, et al. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil 2007; 14: 495–500. [DOI] [PubMed] [Google Scholar]
  • 4. Canales A, Benedí J, Nus M, et al. Effect of walnut‐enriched restructured meat in the antioxidant status of overweight/obese senior subjects with at least one extra CHD‐risk factor. J Am Coll Nutr 2007; 26: 225–232. [DOI] [PubMed] [Google Scholar]
  • 5. Suys B, de Beeck LO, Rooman R, et al. Impact of oxidative stress on the endothelial dysfunction of children and adolescents with type 1 diabetes mellitus: protection by superoxide dismutase? Pediatr Res 2007; 62: 456–461. [DOI] [PubMed] [Google Scholar]
  • 6. Wright E Jr, Scism‐Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006; 60: 308–314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 2007; 67(suppl 1): 43–54. [DOI] [PubMed] [Google Scholar]
  • 8. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007; 9: 33–41. [DOI] [PubMed] [Google Scholar]
  • 9. Cheung BM, Lauder IJ, Lau CP, et al. Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640–651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Wenzel P, Daiber A, Oelze M, et al. Mechanisms underlying recoupling of eNOS by HMG‐CoA reductase inhibition in a rat model of streptozotocin‐induced diabetes mellitus. Atherosclerosis 2008; 198: 65–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Kolovou GD, Katerina A, Ioannis V, et al. Simvastatin: two decades in a circle. Cardiovasc Ther 2008; 26: 166–178. [DOI] [PubMed] [Google Scholar]
  • 12. Ajith TA, Riji T, Anu V. In vitro anti‐oxidant and DNA protective effects of the novel 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008; 35: 625–9. [DOI] [PubMed] [Google Scholar]
  • 13. Roberts WC. The rule of 5 and the rule of 7 in lipid‐lowering by statin drugs. Am J Cardiol 1997; 80: 106–107. [PubMed] [Google Scholar]
  • 14. Sasikala M, Subramanyam C, Sadasivudu B. Early oxidative change in low density lipoproteins during progressive chronic renal failure. Indian J Clin Biochem 1999; 14: 176–183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497–500. [PubMed] [Google Scholar]
  • 16. Moshage H, Kok B, Huizenga JR, et al. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41: 892–896. [PubMed] [Google Scholar]
  • 17. Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984; 105: 114–121. [DOI] [PubMed] [Google Scholar]
  • 18. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended‐release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432–437. [DOI] [PubMed] [Google Scholar]
  • 19. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res 2007; 38: 479–488. [DOI] [PubMed] [Google Scholar]
  • 20. Mihaylova B, Briggs A, Armitage J, et al. Cost‐effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 2005; 365: 1779–1785. [DOI] [PubMed] [Google Scholar]
  • 21. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low‐density lipoprotein. Circ Res 2004; 95: 217–223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Atorvastatin decreases triacylglycerol‐associated risk of vascular events in coronary heart disease patients. Lipids 2007; 42: 999–1009. [DOI] [PubMed] [Google Scholar]
  • 23. Titcolor Stephens JWTitcolor,Titcolor Bain SCTitcolor,Titcolor Humphries SE. Gene‐environment interaction and oxidative stress in cardiovascular disease Atherosclerosis. 2008; 200: 229–238. [DOI] [PubMed] [Google Scholar]
  • 24. Stephens JW, Gable DR, Hurel SJ, et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10‐year risk in a prospective sample of males. Clin Chem 2006; 52: 446–452. [DOI] [PubMed] [Google Scholar]
  • 25. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A–11A. [DOI] [PubMed] [Google Scholar]
  • 26. Zhang M, Zhou SH, Li XP, et al. Atorvastatin downregulates BMP‐2 expression induced by oxidized low‐density lipoprotein in human umbilical vein endothelial cells. Circ J 2008; 72: 807–812. [DOI] [PubMed] [Google Scholar]
  • 27. Ghayour‐Mobarhan M, Lamb DJ, Taylor A, et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. J Trace Elem Med Biol 2005; 19: 61–67. [DOI] [PubMed] [Google Scholar]
  • 28. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild‐to‐moderate AD. Curr Alzheimer Res 2005; 2: 343–353. [DOI] [PubMed] [Google Scholar]
  • 29. Feron O, Dessy C, Desager JP, et al. Hydroxy‐methylglutaryl‐coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113–118. [DOI] [PubMed] [Google Scholar]
  • 30. Espiritu DJ, Mazzone T. Oxidative stress regulates adipocyte apolipoprotein e and suppresses its expression in obesity. Diabetes 2008; 57: 2992–2998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Atamer A, Kocyigit Y, Ecder SA, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol 2008; 21: 924–930. [PubMed] [Google Scholar]
  • 32. Shen WL, Zhong MF, Ding WL, et al. Elevated catalase and heme oxygenase‐1 may contribute to improved postischaemic cardiac function in long‐term type 1 diabetes. Clin Exp Pharmacol Physiol 2008; 35: 820–826. [DOI] [PubMed] [Google Scholar]
  • 33. Brocca L, D'Antona G, Bachi A, et al. Amino acid supplements improve native antioxidant enzyme expression in the skeletal muscle of diabetic mice. Am J Cardiol 2008; 101: 57E–62E. [DOI] [PubMed] [Google Scholar]
  • 34. Kotur‐Stevuljevic J, Spasic S, Jelic‐Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008; 41: 1067–1073. [DOI] [PubMed] [Google Scholar]
  • 35. Farzaneh‐Far A, Libby P, Singh D. Pravastatin, simvastatin, and atorvastatin appear equally effective for preventing cardiovascular events. Evid Based Cardiovasc Med 2006; 10: 135–137. [DOI] [PubMed] [Google Scholar]
  • 36. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged < 65 versus ≥ 65 years with coronary heart disease (from the Incremental Decrease Through Aggressive Lipid Lowering [IDEAL] Study). Am J Cardiol 2009; 103: 577–582. [DOI] [PubMed] [Google Scholar]
  • 37. Jacobson TA, Wertz DA, Hoy T, et al. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated [published correction appears in Mayo Clin Proc. 2009;84:208]. Mayo Clin Proc 2008; 83: 1316–1325. [DOI] [PubMed] [Google Scholar]
  • 38. Marketou ME, Zacharis EA, Nikitovic D, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 2006; 57: 211–218. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES